Close 2026-08-21 1267 scanned A

KIMS

Krishna Institute of Medical Sciences
HealthcareLarge capRs 32,865 crRs 36.9 cr traded a day
Close on 2026-08-21
782.50
−0.95%
52-week range75% of the way up
582.10850.65
Market cap
32,865 cr
P/E (TTM)
169.1×
industry 44×
EPS (TTM)
4.63
Revenue YoY
+35.3%
Q1 FY27
Profit YoY
-56.0%
Net margin
3.2%
-6.6pt vs a year ago
Growth trend
+0.5pt
vs last quarter’s YoY
1 month
+0.1%
Below 52w high
8.7%
RSI (14)
32
Daily swing
2.6%
average true range
Volume
0.5×
vs 20-day average
Traded
Rs 37 cr
median day
Close200-day averageMaterial filing
600700800Aug 25Oct 25Dec 25Feb 26Apr 26Jun 26Aug 26
260 sessions · hover for the filing behind a move
1 week
−3.29%
1 month
+0.12%
3 months
+1.92%
6 months
+5.27%
1 year
+6.18%

The read

written from the numbers on this page
The evidence leans constructive4 supporting, 2 against, 1 worth knowing

Supporting

  • trading 11% above its 200-day average
  • up 6% over twelve months
  • 3 independent kinds of evidence agree today, which is uncommon
  • revenue grew 35% year on year in the quarter ending 2026-06-30

Against

  • net margin has narrowed from 7.5% to 3.2% across four quarters
  • priced at 169× earnings against an industry median of 44× — 284% above its peers

Worth knowing

  • the 50-day and 200-day averages disagree, which usually means a turn in progress rather than a trend to lean on
What would change this read: a close below 707, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.

How it has performed

price return over each window, measured against zero
-3.3%1W+0.1%1M+1.9%3M+5.3%6M+6.2%1Y

What the scans say today

6 of 47 matched on 2026-08-21
KIMS matches 6 of the 47 scans today, across 3 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.

Valuation against its own history

500 sessions since 2024-09-06
64×
median 75×
140×
now 169×
KIMS trades at 169× trailing earnings, above its median of 75× over this window — 127% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.

Recent filings

from the exchange, newest first
Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · Fundraise filings were typically +0.59pt vs the market over the next 5 sessions (n=266)

The business

from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
7777727978729619981.1k1.2k15.5%3.1%3.2%Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.

Going for it

  • revenue grew 35% against the same quarter a year earlier
  • net margin widened from 3.1% to 3.2%
  • revenue rose in 4 of the last 4 quarters

Going against it

  • profit dropped 56% year on year
Quarter-by-quarter numbers, as filed
QuarterRevenueProfit before taxNet profitEPSNet margin
Q1 FY27
2026-06-30 · consolidated
1,18056371.043.2%
Q4 FY26
2026-03-31 · consolidated
1,07552331.063.1%
Q3 FY26
2025-12-31 · consolidated
99869521.335.2%
Q2 FY26
2025-09-30 · consolidated
96197721.677.5%
Q1 FY26
2025-06-30 · consolidated
872114851.969.8%
Q4 FY25
2025-03-31 · consolidated
7971341062.5413.3%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.

Where the price stands

the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-2.6%
Versus 200-day average+10.6%
Below 52-week high-8.0%
Above 52-week low+34.4%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)32.4
Higher closes in last 52 of 5
Six-month return+5.27%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)2.56%
Volume versus 20-day0.5x
Median daily turnoverRs 36.9 cr

Peers

Healthcare · 67 classified companies
KIMS trades at 169.1× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — more expensive than them, by 284%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
CompanyMarket cap (Rs cr)P/E1 month1 yearTurnover (Rs cr)
SUNPHARMA456,44338.3−2.64%+21.54%363.8
DIVISLAB227,82077.9+17.69%+40.46%315.4
TORNTPHARM165,72780.1−3.33%+36.66%212.0
APOLLOHOSP125,00557.6−1.91%+13.16%257.5
CIPLA115,70034.5+2.81%−8.73%119.7
ZYDUSLIFE111,77625.5+0.56%+12.44%112.7
LUPIN100,67718.1−8.12%+16.52%259.0
MANKIND98,45947.6−6.78%−6.26%81.8
DRREDDY98,08730.8+0.72%−6.30%205.2
LAURUSLABS97,35389.3+14.90%+109.51%286.4
MAXHEALTH97,32466.8−7.77%−13.93%185.4
KIMS32,865169.1+0.12%+6.18%36.9
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet